Evidence map›Paper›PMID 32885778›Full record

Observational studyEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020

Increasing proportion of vancomycin-resistance among enterococcal bacteraemias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018.

Vanja Piezzi, Michael Gasser, Andrew Atkinson, Andreas Kronenberg, Danielle Vuichard-Gysin, Stephan Harbarth, Jonas Marschall, Niccolò Buetti, Swiss Centre for Antibiotic Resistance (ANRESIS), National Centre for Infection Control (Swissnoso)

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Vancomycin-resistant Enterococcus faecium: a national wide genomic snapshot in Switzerland.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019-2023.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025
    Article
  6. Article
  7. Trends inMicroorganisms · 2024
    Article
  8. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2018-2022.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024
    Article
  9. Review
  10. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2017-2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023
    Article
  11. Nosocomial outbreak of vancomycin-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022
    Article
  12. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2016-2020.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022
    Article
  13. Article
  14. Replacement ofJAC-antimicrobial resistance · 2021
    Article
  15. Increased Involvement ofHealthcare (Basel, Switzerland) · 2021
    Article
  16. Increasing Trend of Vancomycin-resistant Enterococci Bacteremia in a Tertiary Care Hospital of South India: A Three-year Prospective Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021
    Article
  17. Prevalence of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Vanja PiezziDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Michael GasserInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
Andrew AtkinsonDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Andreas KronenbergInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
Danielle Vuichard-GysinDepartment of Internal Medicine, Cantonal Hospital Muensterlingen, Thurgau Hospital Group, Kreuzlingen, Switzerland.
Stephan HarbarthInfection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Jonas MarschallDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Niccolò BuettiDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Swiss Centre for Antibiotic Resistance (ANRESIS)The members of the advisory board of ANRESIS are acknowledged at the end of the article.
National Centre for Infection Control (Swissnoso)The members of Swissnoso are acknowledged at the end of the article.
University of Bern · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundVancomycin-resistant enterococci (VRE), mostly

Indexed as

Vancomycin ResistanceAgedAged, 80 and overAnti-Bacterial AgentsBacteremiaCross InfectionEnterococcus faecalisEnterococcus faeciumHumansMicrobial Sensitivity TestsMiddle AgedPopulation SurveillanceRetrospective StudiesSwitzerlandVancomycinAnti-Bacterial AgentsVancomycinbacteraemiaEnterococciepidemiologysurveillanceVancomycin resistantVRE

Identifiers

PMID32885778
PMCPMC7472687
OpenAlexW3082681966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.